Mar 16–19, 2025 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Christian U Blank, Stefani Spranger, and Anna Christina Obenauf

-
Scientific Organizers: Christian U Blank, Stefani Spranger, and Anna Christina Obenauf
Christian U Blank
Stefani Spranger
Anna Christina Obenauf
***Meeting program subject to change.
Available Formats: = In Person = On DemandMerchandise Options
Registration Options
Sunday, March 16, 2025
Fundraising
Booking Function
Monday, March 17, 2025
Session Chair
Session Chair
Cell Therapies: Current State of the Art
Dissecting T Cell Recognition of Cancer
Genomic Regulation of CAR T Cell Driven Dysfunction
Rational Combination Therapies to Stimulate the APC Compartment
Metabolic Interventions to Enhance Adoptive Cellular Therapies
AI/ML-Driven Discovery of a Novel Proteoglycan for Precision Targeting of Solid Tumors by T Cell Engagers
A STUB1-CHIC2 Complex Decreases IL-27Rα Expression on CD8+ T Cells To Restrain Tumor Immunity
ICOS Limits Memory-like Properties and Function of Exhausted PD-1+ CD8 T Cells
IDO1 - Revising Dogma to Improve Control
The eATP Receptor P2RX7 Promotes Optimal Progenitor Exhausted CD8+ T Cell Responses To Anti-PD1 Blockade
Interrogating Immune Archetypes & Tumor Sampling to Inform Therapy
Metabolic Control of Anti-Tumor Immunity
Personalized Neoantigen Vaccines in Cancer Immunotherapy
Short Talk: Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma With an Immune-Excluded Phenotype
Short Talk: Tumor-resident CD103+ CD11b+ Dendritic Cells are Associated with Poor Anti-Tumor Immunity in Ovarian Cancer
Tuesday, March 18, 2025
Neoadjvant Cancer Immunotherapy in NSCLC
Personalized Neoadjuvant Cancer Immunotherapy in Melanoma
Short Talk: Insights from Single-Cell Resolution Spatial Transcriptomic Analysis Before and During Neoadjuvant Immunotherapy in Advanced Melanoma
Short Talk: Untangling and Applying the Paradoxical Immune Sensitivity of Sarcomatoid Renal Cell Carcinoma
Short Talk: Mechanistic Insights into the Paradoxical Efficacy of JAK and PD1 Inhibition in Cancer Immunotherapy
Professor and Director
Associate Professor
Chief Scientific Officer
CSO Partner
Deputy Editor
DC Determine Quality of T Cell Responses
Affinity Selection Phase during CD8 T Cell Priming
NK Cell Therapeutics
Short Talk: Intra-tumoral Treg Ablation Activates a CD4-NK Cell Axis to Control MHC Class I-deficient Tumors
Short Talk: Alterations in MAIT Cells Frequency and Function During Melanoma Development and Treatment
Wednesday, March 19, 2025
Remote Presentation: Anchored Cytokines for the Treatment of Cancer
Chemokine Signaling and Positioning in the LN
Cytokine Engineering
Short Talk: Unmasking the Potential of Cytokines for Cancer Immunotherapy: Lessons Learned from the Early Clinical Development of Tumor-activated IL-2 and IL-12 INDUKINE Molecules
Short Talk: A New PD-L1 Antibody Degrades PD-L1 and Sensitizes Cancer Cells to Cytotoxic Therapy
Short Talk: Development of Novel “Myeloid-Targeted Immunocytokine and (NK)T cell Enhancer” (MiTE) with Tumor-Conditioned Cytokine Activity for Cancer Treatment Using Single Cell Genomics and AI
Developing Discovery Proteomics Technologies to Elucidate HLA Neoantigen Presentation
CMTM4/6 as Novel Therapeutic Targets to Sensitize Hepatocellular Carcinoma to Immunotherapy
Characterising Novel Protein Tools for Potentiating T Cell Activation by Inhibiting PD-1
Progesterone Promotes Immunosuppression in Murine Mammary Tumors by Modulating T Cell Infiltration and Function
Novel Type I-Type III IFN Fusion Proteins For Cancer Therapy
Remote Presentation: Engineering of Myeloid Cells
Nature Inspired Design
CRISPR-Based T Cell Editing to Enhance Cell Therapy
Thursday, March 20, 2025
Subscribe for Updates